Last reviewed · How we verify
Mvix (MIRODENAFIL)
Mirodenafil (Mvix) is a marketed drug indicated for impotence, operating through the inhibition of an enzyme that allows for increased blood flow. Its key competitive advantage lies in its unique mechanism of action and the protection offered by its key composition patent, which does not expire until 2028. The primary risk to Mirodenafil's market position is the presence of off-patent competitors such as avanafil and dipyridamole, which are already available as generics.
At a glance
| Generic name | MIRODENAFIL |
|---|---|
| Target | cGMP-specific 3',5'-cyclic phosphodiesterase |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Impotence
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction
- Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg (PHASE1)
- Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg (PHASE1)
- Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mvix CI brief — competitive landscape report
- Mvix updates RSS · CI watch RSS